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SUMMARY. It is unclear whether the current threshold for
high hepatitis C virus (HCV) RNA level (800 000 IU/mL) is
optimal for predicting sustained virological response (SVR).
We retrospectively analysed pretreatment HCV RNA levels
and SVR rates in 1529 mono-infected and 176 HIV–HCV
co-infected patients treatedwith peginterferon alfa-2a (40 kD)
plus ribavirin. We improved the threshold for differentiating
low and high viral load by fitting semiparametric generalized
additive logistic regression models to the data and construct-
ing receiver operating characteristics curves. Among HCV
genotype 1mono-infected patients, the difference in SVR rates
between those with low and high baseline HCV RNA levels
was 27% (70% vs 43%) when 400 000 IU/mL was used and
16% (59% vs 43%) when 800 000 IU/mL was used. In HIV–
HCV genotype 1 co-infected patients, the difference was 51%
(71% vs 20%)when 400 000 IU/mLwas used and 43% (61%
vs 18%) when 800 000 IU/mL was used. A lower threshold
(200 000 IU/mL)was identified for genotype 1mono-infected
patients with normal alanine aminotransferase (ALT) levels.
No threshold could be identified in HCV genotype 2 or 3
patients. A threshold HCV RNA level of 400 000 IU/mL is
optimal for differentiating high and low probability of SVR in
genotype 1-infected individuals with elevated ALT.
Keywords: alanine aminotransferase, baseline predictor, HCV
genotype 1, HCV viral load, sustained virological response.
Hepatitis C virus (HCV) genotype and pretreatment HCV
RNA level are important determinants of the outcome of
treatment with pegylated interferon plus ribavirin [1,2].
Infection with HCV genotype 1 and the presence of a high
baseline HCV RNA level portends a lower probability of
sustained virological response (SVR) [1–3]. A high
HCV RNA level was originally defined as >2 · 106 copies/
mL [4] on the basis of the results of phase 3 studies of
conventional interferon alfa-2b plus ribavirin [5,6]. This
definition was utilized in phase 3 registration trials of
peginterferon alfa-2a in monotherapy [7–9] and in combi-
nation with ribavirin [10–12]. Serum HCV RNA levels have
since been standardized and reported in International Units
(IU) [13]. Despite this, the cut-off between high and low viral
load has not been modified, and the current licences for these
products continue to reflect the older data.
The time required to become HCV RNA undetectable after
initiating treatment impacts the rate of SVR, and this
information can be utilized to adjust treatment duration.
Patients with HCV genotype 1, a rapid virological response
(RVR) and low viral load have similar rates of SVR whether
treated for 24 or 48 weeks [2]. Consequently in the EU, 24
or 48 weeks of treatment with peginterferon alfa-2a plus
ribavirin is recommended for HCV genotype 1 and 4 patients
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with a low baseline viral load and RVR [14]. In this rec-
ommendation, the definition utilized for low viral load was
<600 000 or <800 000 IU/mL. Furthermore, an abbrevi-
ated 16-week regimen of peginterferon alfa-2a plus ribavirin
has been licensed in the EU for patients infected with HCV
genotypes 2 or 3 with a low HCV RNA level [14]. Similar
recommendations have been suggested for patients with HIV
and HCV co-infection and genotypes 2 and 3 [15].
Patients achieving an RVR with a high pretreatment
serum HCV RNA level have a lower probability of achieving
an SVR than those with a low level when treated with
abbreviated regimens [16–19]. Thus, in the era of response-
guided therapy, a precise definition of what constitutes a low
and high HCV RNA level is needed.
We analysed pretreatment HCV RNA levels and SVR rates
in patients treated with the combination of peginterferon
alfa-2a (40 kD) plus ribavirin in several randomized inter-
national phase 3 trials.
METHODS
This retrospective analysis included data from randomized,
phase 3 trials of peginterferon alfa-2a (40 kD) plus ribavirin
[10,11,19–21]. Four trials recruited HCV mono-infected pa-
tients; in three of these studies, patients had elevated serum
alanine aminotransferase (ALT) levels at baseline [10,11,19],
one ofwhichwas restricted to patientswithHCVgenotype2 or
3 infection [19]. Only noncirrhotic patients with persistently
normal ALT levels were eligible for the fourth study [20]. We
also analysed data from the APRICOT trial, which enrolled
patients with HIV–HCV co-infection [21].
The HCV mono-infected patients with elevated ALT levels
included in this analysis were treated with peginterferon
alfa-2a (40 kD) 180 lg per week plus ribavirin 1000/
1200 mg per day for 48 weeks (HCV genotype 1 infection)
or peginterferon alfa-2a (40 kD) 180 lg per week plus
ribavirin 800 mg per day for 24 weeks (HCV genotype 2 or
3 infection). The genotype 1-infected patients with persis-
tently normal ALT levels and the genotype 1-infected
patients with HIV–HCV co-infection included in this analysis
were treated with peginterferon alfa-2a (40 kD) 180 lg per
week plus ribavirin 800 mg per day for 48 weeks.
Measurement of serum HCV RNA levels
Serum HCV RNA levels were quantified with the COBAS
AMPLICOR HCV MONITOR Test, v2.0 (limit of quantitation
600 IU/mL; Roche, Rotkreuz, Switzerland). Samples were
analysed using the COBAS AMPLICOR HCV Test, v2.0, limit
of detection 50 IU/mL (Roche, Pleasanton, CA, USA).
Primary efficacy outcome
The primary efficacy endpoint in each trial was SVR, defined
as undetectable HCV RNA by the qualitative PCR assay
(<50 IU/mL) at the end of a 24-week untreated follow-up
period.
Data analysis
The association between pretreatment serum HCV RNA
level and SVR was examined by multiple logistic regres-
sion (MLR) analysis. Factors considered for inclusion in
the MLR models were pretreatment serum HCV RNA
level (log10 IU/mL), age, body weight and ALT quotient,
gender (male vs female), histological diagnosis (cirrhosis/
transition to cirrhosis vs no cirrhosis/transition to fibrosis)
and race.
To evaluate the possibility of nonlinear associations
between continuous explanatory factors and SVR, a semi-
parametric generalized additive logistic regression model
(GAM) was fitted to the data [22]. For ease of interpretation,
and to visualize the relationship between SVR and viral load,
the probability of SVR was plotted as a function of log10
pretreatment HCV RNA values using univariate GAM
curves. Receiver operating characteristics (ROC) curves of
pretreatment serum HCV RNA level were plotted for the
prediction of SVR. These show the true-positive fraction
(TPF = sensitivity) and corresponding false-positive fraction
(FPF = 1)specificity) for each of the observed HCV RNA
values used as a cut-off to predict SVR.
SAS version 8.2 software and S-PLUS were used in all
statistical analyses.
RESULTS
Data from 1529 patients with HCV mono-infection, includ-
ing 140 with persistently normal serum ALT, and 176 pa-
tients with HIV–HCV co-infection, were included in the
analysis. The baseline characteristics of these individuals are
presented in Table 1.
Patients with HCV mono-infection
HCV genotype 1, elevated serum ALT levels
Baseline factors predictive of SVR in the MLR analysis of data
from HCV mono-infected genotype 1 patients with elevated
serum ALT levels included lower pretreatment HCV RNA
level (P < 0.0001), higher ALT quotient (P < 0.0001),
lower body weight (P = 0.0003), younger age (P = 0.0012)
and absence of advanced liver fibrosis (P = 0.0356)
(Table 2). Analysis of the linearity of the logit for SVR
indicated a nonlinear effect of pretreatment HCV RNA level
and age.
The semiparametric GAM analysis showed a decrease in
SVR with increasing HCV RNA values in the range from
4 log10 to 6 log10 IU/mL. For example, in a patient with
a pretreatment HCV RNA level of 5.6 log10 IU/mL
(400 000 IU/mL) (and any set of disease characteristics),
the probability of an SVR was identical to that for a patient
 2012 Blackwell Publishing Ltd
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with the same set of disease characteristics when HCV
RNA levels in the model were ignored. Similarly, a uni-
variate GAM analysis with pretreatment HCV RNA level as
the exploratory variable showed that the probability of an
SVR at an HCV RNA level of 400 000 IU/mL was 0.5,
which is close to the crude SVR rate (Fig. 1a). For HCV
RNA values above 400 000 IU/mL, the curve of predicted
SVR probabilities is flat, and the decrease in SVR rate is
moderate.
These findings are consistent with the observed SVR rates
shown in Fig. 2a. Among patients with a pretreatment HCV
RNA level £400 000 IU/mL, the SVR rate was 70% (91/
Table 1 Baseline characteristics of patients included in the analysis
Characteristic
HCV mono-infection (n = 1529)
HIV–HCV genotype
1 co-infection
(n = 176)
Elevated ALT levels (n = 1389)
Persistently normal
ALT levels
Genotype 1
(n = 568)
Genotype 2
(n = 395)
Genotype 3
(n = 426)
Genotype 1
(n = 140)
Male, n (%) 388 (68.3) 238 (60.3) 283 (66.4) 54 (38.6) 146 (83)
Age*, years 43.8 ± 10.4 48.7 ± 9.5 41.5 ± 9.4 44.1 ± 9.6 39.8 ± 7.9
Weight*, kg 79.6 ± 16.9 83.6 ± 19.1 79.0 ± 17.1 75.1 ± 17.6 73.0 ± 14.1
BMI*, kg/m2 26.9 ± 4.9 28.4 ± 5.8 26.5 ± 5.0 26.6 ± 5.3 24.5 ± 4.4
Race, n (%)
Caucasian 485 (85.4) 336 (85.1) 386 (90.6) 120 (85.7) 137 (77.8)
Non-Caucasian 83 (14.6) 59 (14.9) 40 (9.4) 20 (14.3) 39 (22)
Histological diagnosis, n (%)
No cirrhosis 452 (79.6) 298 (75.4) 338 (79.3) 139 (99.3) 152 (86.4)
Bridging fibrosis/cirrhosis 116 (20.4) 97 (24.6) 88 (20.7) 0 24 (13.6)
Unknown 0 0 0 1 (0.7) 0
ALT, alanine aminotransferase. *Values are mean ± standard deviation.
Table 2 Multiple logistic regression analysis of explanatory factors for SVR in HCV genotype 1 patients
Factor
HCV mono-infection HIV–HCV co-infection
Elevated ALT levels
(n = 568)
Normal ALT levels
(n = 138)
Elevated ALT levels
(n = 176)
Odds ratio (95% CI); P-value Odds ratio (95% CI); P-value
Odds ratio (95% CI);
P-value
HCV RNA per
1-log10 IU/mL
increment
0.524 (0.388–0.708);
P < 0.0001
0.362 (0.160–0.822);
P = 0.0152
0.312 (0.186–0.523);
P < 0.0001
ALT ratio per
1-unit decrement
0.821 (0.744–0.906);
P < 0.0001
0.505 (0.045–5.619);
P = 0.5780
0.741 (0.566–0.969);
P = 0.0284
Body weight per
10-kg increment
0.802 (0.712–0.904);
P = 0.0003
0.808 (0.637–1.024);
P = 0.0778
0.830 (0.589–1.168);
P = 0.2851
Age per 10-year
increment
0.737 (0.613 to )0.887);
P = 0.0012
0.806 (0.542–1.196);
P = 0.2841
0.710 (0.415–1.215);
P = 0.2116
Bridging fibrosis/
cirrhosis (yes vs no)
0.604 (0.378–0.967);
P = 0.0356
NA 0.370 (0.103–1.327);
P = 0.1271
Race (non-Caucasian vs
Caucasian)
0.697 (0.418–1.162);
P = 0.1665
0.350 (0.102–1.196);
P = 0.0939
0.963 (0.344–2.696);
P = 0.9431
Gender (male vs female) 0.887 (0.585–1.347);
P = 0.5746
0.756 (0.320–1.785);
P = 0.5236
0.608 (0.214–1.731);
P = 0.3516
ALT, alanine aminotransferase; SVR, sustained virological response.
 2012 Blackwell Publishing Ltd
768 S. Zeuzem et al.
130). The SVR rate was considerably lower among patients
with an HCV RNA level >400 000 IU/mL (43%; 188/438).
Thus, when 400 000 IU/mL was selected as the cut-off, the
difference in SVR rate was 27%. By contrast, when using the
conventional cut-off of 800 000 IU/mL, the difference in
SVR rate decreased to 16% (Fig. 2a). Interestingly, the rate
of SVR in patients with a high viral load was the same (43%)
irrespective of whether the cut-off was defined as 400 000 or
800 000 IU/mL.
The appropriateness of the 400 000 IU/mL cut-off was
confirmed by the ROC analysis. The point on the ROC
curve that maximizes the vertical distance from the 45-
degree line is close to 400 000 IU/mL and represents the
cut-off with the lowest total error rate (TPF + FPF) and
with the maximal sum of sensitivity (TPF) and specificity
(1)FPF) (Fig. 3a). The sensitivity of a cut-off of
400 000 IU/mL was 0.33, and the specificity was 0.87.
The positive and negative predictive values were 0.70 and
0.57, respectively.
Genotype 1, persistently normal serum ALT levels
Baseline serum HCV RNA level was the only factor that
significantly predicted SVR (odd ratio [OR] 0.362, 95%
confidence interval [CI]: 0.160, 0.822; P = 0.0152) in the
MLR analysis of data from genotype 1-infected patients with
normal ALT levels (Table 2). Other exploratory factors
showed the same trends as those for genotype 1-infected
patients with elevated ALT levels.
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Fig. 1 Generalized additive logistic regression model plotting the effect of hepatitis C virus (HCV) RNA (log10 IU/mL) on the
probability of achieving a sustained virological response (SVR). Higher values on the vertical scale correspond to a higher
probability of predicting an SVR, while a value of 0.5 corresponds to no contribution towards predicting SVR. (A) HCV
genotype 1-infected patients with elevated alanine aminotransferase (ALT) levels; (B) HCV genotype 2-infected patients with
elevated ALT levels; (C) HCV genotype 3-infected patients with elevated ALT levels; (D) HCV genotype 1-infected patients with
persistently normal serum ALT levels; (E) HCV genotype 1-infected patients co-infected with HIV.
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The general shape of the GAM curve for patients with
normal ALT levels (Fig. 1d) is similar to that for patients
with elevated ALT levels (Fig. 1a). However, when compared
with patients with elevated ALT levels, the decrease in the
probability of SVR for each 1 )log10 drop in HCV RNA level
is greater for patients with normal ALT levels, and the
probability of SVR is lower for individuals with pretreatment
HCV RNA values above 100 000 IU/mL.
Among patients with normal ALT levels, the probability
of achieving an SVR was 50% for individuals with a pre-
treatment HCV RNA level of 5.25 log10 IU/mL
(180 000 IU/mL) and was 40% (identical to the overall
observed SVR rate) for individuals with a pretreatment HCV
RNA level of 5.41 log10 IU/mL (260 000 IU/mL).
The point on the ROC curve that maximized the vertical
distance from the 45-degree line and therefore minimized
the total error rate corresponded to a pretreatment
HCV RNA level of 5.21 log10 IU/mL (163 000 IU/mL)
(Fig. 3d).
The sensitivity (TPF) for a cut-off of 163 000 IU/mL was
0.36, and the specificity (1)FPF) was 0.93. The positive
predictive value and negative predictive value were 0.77 and
0.68, respectively.
When a pretreatment HCV RNA level of 163 000 IU/mL
was selected as the cut-off to differentiate low from high
pretreatment viral load, the difference in SVR rates was 45%
(77% vs 32%). The use of higher cut-offs resulted in lower
differences in SVR rates: 34% if the cut-off was set at
200 000 IU/mL (66% vs 32%) (Fig. 2b); 16% if the cut-off
was set at 400 000 IU/mL (49% vs 33%) (Fig. 2b); and 20%
if the cut-off was set at 800 000 IU/mL (47% vs 27%).
Genotype 2 or 3, elevated serum ALT levels
An MLR analysis of data from all patients infected with
genotype 2 or 3 (n = 818) demonstrated that HCV genotype
(OR 0.373 for genotype 3 vs genotype 2, 95% CI: 0.258,
0.541; P £ 0.0001) was a significant predictor of SVR.
Therefore, separate models were constructed for each
genotype. The factors predictive of SVR were similar in both
analyses, although baseline serum HCV RNA level was a
more important predictor of SVR for genotype 3-infected
patients and a diagnosis of bridging fibrosis/cirrhosis was a
more important predictor of SVR for genotype 2-infected
patients.
Significant predictors of lower SVR among genotype 2-
infected patients included histological diagnosis (OR 0.359
for bridging fibrosis/cirrhosis vs minimal fibrosis, 95% CI:
0.202, 0.635; P = 0.0004), lower ALT quotient (OR 0.810,
95% CI: 0.691, 0.949; P = 0.0094), higher body weight
(OR 0.824 per 10 kg, 95% CI: 0.714, 0.950; P = 0.0078)
and higher pretreatment HCV RNA level (OR 0.688, 95% CI:
0.483, 0.980; P = 0.038).
Among genotype 3-infected patients, lower SVR was pre-
dicted by histological diagnosis (OR 0.539 for bridging
fibrosis/cirrhosis, 95% CI: 0.313, 0.927; P = 0.0256), lower
ALT quotient (OR 0.814, 95% CI: 0.698, 0.948;
P = 0.0083), higher bodyweight (OR 0.774 per 10 kg, 95%
CI: 0.670, 0.893; P = 0.0005) and higher pretreatment
HCV RNA level (OR 0.590, 95% CI: 0.435, 0.801;
P = 0.0007).
The GAM analysis for genotype 2-infected patients showed
that SVR decreased with increasing HCV RNA level up to
100 000 IU/mL, remained fairly constant (80%)
between 100 000 IU/mL and 1 000 000 IU/mL and
decreased thereafter (Fig. 1b). Among patients with HCV
genotype 3 infection, SVR declined at a fairly constant rate
over the range of values encountered (Fig. 1c) and remained
>60% for all patients, including those with very high HCV
RNA levels.
In contrast to patients infected with HCV genotype 1, ROC
curves for patients infected with HCV genotypes 2 or 3
Pa
tie
nt
s 
w
ith
 a
n 
SV
R
 (%
)
Baseline HCV RNA level (IU mL–1)
100
70
∆ = 27%
∆ = 16%
43
59
43
≤400 000 >400 000 ≤800 000 >800 000
80
60
40
20
0
Baseline HCV RNA level (IU mL–1)
Pa
tie
nt
s 
w
ith
 a
n 
SV
R
 (%
)
∆ = 34%
66
21
32
35
108
30
61
26
79
32
49
33
∆ = 16%
100
90
70
50
30
10
≤200 000 >200 000 ≤400 000 >400 000
80
60
40
20
0
Baseline HCV RNA level (IU mL–1)
Pa
tie
nt
s 
w
ith
 a
n 
SV
R
 (%
) ∆ = 51%
71
22
31
29
145
28
46
23
130
20
61
18
∆ = 43%
100
90
70
50
30
10
≤400 000 >400 000 ≤800 000 >800 000
80
60
40
20
0
(a)
(b)
(c)
Fig. 2 Difference in sustained virological response (SVR)
rates between genotype 1 patients with high and low pre-
treatment hepatitis C virus (HCV) RNA levels. The impact of
different thresholds to define low serum HCV RNA level
(£400 000 and £800 000 IU/mL) on the difference (D) in
SVR rates between patients with low and high serum HCV
RNA levels. (a) HCV mono-infected patients with elevated
alanine aminotransferase (ALT) levels; (b) HCV mono-in-
fected patients with persistently normal ALT levels; (c)
HIV–HCV co-infected patients.
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Fig. 3 Receiver operating characteristic curve of pretreatment hepatitis C virus (HCV) RNA level for the prediction of sus-
tained virological response rate. (a) HCV genotype 1-infected patients with elevated serum alanine aminotransferase (ALT)
levels; (b) HCV genotype 2-infected patients with elevated ALT levels; (c) HCV genotype 3-infected patient with elevated ALT
levels; (d) HCV genotype 1-infected patients with persistently normal serum ALT levels; (e) HIV–HCV genotype 1 co-infected
patients with elevated ALT level.
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revealed no obvious cut-off to discriminate between
responders and nonresponders (Figs. 3b,c). Moreover, the
differences in SVR rate between patients with low and high
pretreatment HCV RNA levels when cut-offs of 400 000 and
800 000 IU/mL were selected were 9% (84% vs 75%) and
10% (84% vs 74%), respectively, for genotype 2-infected
patients and 15% (79% vs 64%) and 13% (76% vs 63%),
respectively, for genotype 3-infected patients.
Genotype 1-infected patients with HIV–HCV co-infection
Baseline serum HCV RNA level and ALT ratio were the only
significant factors that predicted SVR in the MLR analysis of
data from HIV–HCV co-infected patients (Table 2). All other
exploratory factors showed the same predictive trends as
observed for genotype 1-infected patients with elevated ALT
levels.
The general shape of the GAM curve was similar to that
from patients with HCV genotype 1 mono-infection (Fig. 1e).
The steepest slope of the curve and the point at which the
curve crosses the 0.5 line coincides with an HCV RNA level
of 5.6 log10 IU/mL (400 000 IU/mL).
The point on the ROC curve that minimized the total error
rate corresponded to a pretreatment HCV RNA level of 6.32
log10 IU/mL (2 100 000 IU/mL) (Fig. 3e). The sensitivity
(TPF) for a cut-off of 2 100 000 IU/mL was 0.71, while the
specificity (1)FPF) was 0.74. The positive and negative
predictive values were 0.52 and 0.86, respectively. When,
instead of the minimal total error rate of a cut-off, the simple
difference in SVR rates was used to differentiate between
patients with low and high pretreatment HCV RNA; the
value of 2 100 000 IU/mL was not optimal. The difference
in SVR rate was 38% (52% vs 14%, respectively) for this cut-
off, while for a cut-off of 400 000 IU/mL, the difference in
SVR rate was 51% (71% vs 20%) and 43% (61 vs 18%) for
the cut-off of 800 000 IU/mL (Fig. 2c).
DISCUSSION
This analysis confirms that SVR decreases with increasing
viral load in patients infected with HCV genotypes 1, 2 or 3.
The analysis extends our understanding for HCV genotype 1
patients by showing that the optimal cut-off that differenti-
ates between high and low viral load is lower than the tra-
ditional threshold. The analysis also shows that for genotype
2 or 3 infection, the concept of high and low viral load is less
relevant, and no defined cut-off can clearly differentiate high
from low baseline viral load.
The difference in SVR rate between mono-infected patients
with low and high baseline serum HCV RNA levels was
considerably greater when the threshold was set at
400 000 IU/mL (27%) than when it was set at 800 000 IU/
mL (16%). This is noteworthy because a definition of
800 000 IU/mL for high HCV RNA level has historically
been used to define high serum HCV RNA levels in numer-
ous guidelines for the treatment of chronic hepatitis C
[4,23,24] and is reflected in the current licences for pegy-
lated interferons.
Our findings are consistent with those of two other anal-
yses in patients infected with HCV genotype 1, both of which
identified a critical threshold of 400 000 IU/mL using the
ROC curve method of analysis [25,26]. In the first of these
studies, the rate of SVR was 70% among patients with pre-
treatment serum HCV RNA levels £400 000 IU/mL com-
pared with 46% among those with pretreatment serum HCV
RNA levels >400 000 IU/mL (difference 24%; P < 0.0001).
By contrast, SVR was 58% among patients with pretreat-
ment serum HCV RNA levels £800 000 IU/mL compared
with 45% among those with pretreatment serum HCV RNA
levels >800 000 IU/mL (difference 13%; P = 0.007) [25].
The results of the analysis in HCV genotype 1-infected
patients with elevated serum ALT levels show that a pre-
treatment serum HCV RNA level of 5.6 log10 IU/mL
(400 000 IU/mL) is the threshold that offers an improved
discrimination between a high and low probability of
achieving an SVR. The definition applies to both HCV mono-
infected and HIV–HCV co-infected patients. By contrast, a
lower threshold (200 000 IU/mL) appears to be more
appropriate for HCV genotype 1 mono-infected patients with
persistently normal serum ALT levels. In contrast to the
findings in patients infected with HCV genotype 1, the
analyses of data from patients infected with HCV genotypes
2 or 3 did not identify a fixed threshold that can be used to
differentiate patients with a high or a low probability of
achieving an SVR.
Taken together, the results of our analysis and the studies
of abbreviated therapy suggest that the pretreatment HCV
RNA level should be an important component of response-
guided therapy algorithms primarily for genotype 1-infected
patients. Among patients with an RVR, those with pre-
treatment HCV RNA levels £400 000 IU/mL are the best
candidates for abbreviated therapy; and those with higher
HCV RNA levels retain a high likelihood of achieving an
SVR, but they would be better managed with the full
48-week treatment duration.
Data from a trial conducted exclusively in patients infected
with HCV genotypes 2 or 3 show that abbreviated therapy is
less successful for patients with high pretreatment HCV RNA
levels [19]. Among patients treated for 24 weeks with
peginterferon alfa-2a (40 kD) plus ribavirin, the difference in
the rate of SVR between those with a pretreatment serum
HCV RNA level of £400 000 IU/mL and those with
>400 000 IU/mL was 13% (81% vs 68%, respectively), and
among patients treated for 16 weeks, the difference in SVR
rate was 25% (82% vs 57%). On this basis, the authors
concluded that abbreviated therapy should only be
contemplated for HCV genotype 2- or 3-infected patients
with a pretreatment HCV RNA level £400 000 IU/mL [27].
Although in the present analysis we have shown that a
threshold of 400 000 IU/mL may be more discriminating
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than a threshold of 800 000 IU/mL, it remains to be
determined what, if any, threshold may be optimal among
patients receiving peginterferon plus ribavirin in combina-
tion with new therapies, such as HCV protease inhibitors.
Recently, it has been shown that a genetic variation asso-
ciated with the IL28B gene that confers an improved SVR to
patients with genotype 1 treatment-naive HCV infection [28].
This genetic polymorphism is associated with an approxi-
mately twofold change in response to treatment and is more
predictive than viral load and fibrosis stage [29]. As such, we
will likely be testing for the IL28B allele prior to initiation of
treatment as soon as assays are commercially available. This
may diminish, but will certainly not eliminate, the importance
of pretreatment viral load in genotype 1 patients.
In conclusion, among patients with HCV genotype 1
infection and elevated serum ALT levels, a pretreatment
serum HCV RNA level of 400 000 IU/mL is an optimized
threshold for differentiating between patients with a high
and low probability of achieving an SVR when treated for
48 weeks with peginterferon alfa-2a (40 kD) plus ribavirin.
The threshold can be applied in the setting of HCV mono-
infection and HIV–HCV co-infection. In the era of response-
guided therapy, this threshold may be useful for identifying
the HCV mono-infected patients who are most likely to
respond to an abbreviated treatment regimen.
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